Achillion Pharmaceuticals

INVESTORS

Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Sep 20, 2017	Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series NEW HAVEN, Conn., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will provide a corporate update at the 2017 Leerink Partners Rare Disease Roundtable Series on Wednesday, September 27, 2017 at 10:00 a.m.	View HTML Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series 11.2 KB
Toggle Summary Oct 23, 2017	Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting - 98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6 -	View HTML Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting 15.1 KB
Toggle Summary Oct 24, 2017	USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to Achillion for ACH-4471. U.S. Patent No. 9,796,741, entitled "Aryl, Heteroaryl, and Heterocyclic Compounds	View HTML USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor 14.9 KB
Toggle Summary Nov 1, 2017	Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program in PNH and C3G	View HTML Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 34.6 KB
Toggle Summary Nov 6, 2017	Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).	View HTML Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 16.6 KB
Toggle Summary Nov 14, 2017	Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G - Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471 - - Improvement in complement alternative pathway biomarkers observed - NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.	View HTML Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 26 KB
Toggle Summary Nov 14, 2017	Achillion Announces Proposed Secondary Offering of Common Stock NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced that Johnson & Johnson Innovation-JJDC, Inc. ("JJDC"), an existing stockholder of Achillion, intends to offer for sale in an underwritten public offering 18,367,346 shares	View HTML Achillion Announces Proposed Secondary Offering of Common Stock 26 KB
Toggle Summary Nov 15, 2017	Achillion Announces Pricing of Secondary Offering Of Common Stock NEW HAVEN, Conn., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc.	View HTML Achillion Announces Pricing of Secondary Offering Of Common Stock 12.1 KB
Toggle Summary Dec 18, 2017	Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study - Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) — - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers— NEW HAVEN, Conn., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,	View HTML Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 16.8 KB
Toggle Summary Dec 20, 2017	Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today announced that the Company has begun dosing subjects in a	View HTML Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 15.1 KB